HKSE · 1753.HK
Duiba Group Limited
HK$0.89+HK$0.08 (+9.88%)
Duiba Group Limited’s quoted price sits in the upper half of its reported 52-week range, 29.92% below the high.
Loading market information…
HKSE · 6833.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 28, 2026, 07:40 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sinco Pharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 34.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sinco Pharmaceuticals Holdings Limited’s forward annual dividend is HK$0.00 per share, paid annual. The forward yield is 1.11% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sinco Pharmaceuticals Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| HK$1.02B |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$0.89+HK$0.08 (+9.88%)
Duiba Group Limited’s quoted price sits in the upper half of its reported 52-week range, 29.92% below the high.
HK$0.76HK$0.00 (0.0%)
ShiFang Holding Limited’s quoted price sits in the upper half of its reported 52-week range, 28.77% below the high.
HK$0.40-HK$0.01 (-1.23%)
BFB Health Limited’s quoted price sits in the lower half of its reported 52-week range, 60.4% below the high.
HK$0.61-HK$0.01 (-0.82%)
Hong Kong Economic Times Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 28.82% below the high.
HK$0.22-HK$0.01 (-4.35%)
Pacific Online Limited’s quoted price sits in the lower half of its reported 52-week range, 44.3% below the high.
HK$0.14-HK$0.01 (-5.92%)
Culturecom Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 42.8% below the high.
HK$0.44HK$0.00 (0.0%)
Asiaray Media Group Limited’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
HK$0.25HK$0.00 (0.0%)
Bright Future Technology Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 63.43% below the high.
